Primary Care/Hospitalist
RSSArticles
-
Stable Coronary Disease and Atrial Fibrillation Patients Best Treated With Rivaroxaban Alone
Monotherapy with rivaroxaban was noninferior to combination therapy for the primary efficacy endpoint of composite of stroke, systemic embolism, myocardial infarction, unstable angina, or death from any cause.
-
What Is the Optimal Blood Pressure for Secondary Prevention of Stroke?
Investigators terminated a study early before they could draw any firm conclusions. Thus, there remains a lack of solid evidence to support a firm recommendation regarding optimal blood pressure management for secondary stroke prevention.
-
Dapagliflozin Treatment Improves Life Quality for Systolic Heart Failure Patients
Treatment with dapagliflozin for 12 weeks resulted in improved health status, either a reduction in NT-proBNP or improvement in quality of life measures, in systolic heart failure patients with or without type 2 diabetes mellitus.
-
Menopausal Hormonal Therapy and Breast Cancer Risk: Are Old Data Relevant to Today’s Practice?
An individual-participant meta-analysis of prospective studies revealed menopausal hormone therapy associated with an elevation in the risk of breast cancer, with the highest risks associated with daily combined therapy.
-
Taming of the Flu: What’s New for 2020
The 2019-2020 flu season is already among us, and it is imperative that those healthcare practitioners on the frontline have current knowledge of prevention and treatment strategies. Both influenza A and B strains have been identified, and their predominance varies by region and age group.
-
Researchers Examine Use of Dichloroacetate in Endometriosis Treatment
The authors of a new scientific paper indicate that dichloroacetate, investigated as a potential cancer treatment, may be effective against endometriosis. Finding a new treatment option would augment current treatment strategies of hormone therapy and surgery, which involve significant side effects and recurrence after treatment.
-
Research Focuses on Medroxyprogesterone Acetate in Cervical Cancer Prevention
Preliminary research suggests that medroxyprogesterone acetate, the active ingredient in the contraceptive injection DMPA, may be effective in preventing cervical cancer.
-
Policy Update Advocates Teen Access to Emergency Contraception
To help prevent unplanned pregnancy among adolescents, the American Academy of Pediatrics has issued an updated policy statement on emergency contraception (EC) to educate providers on use of EC in adolescents, and advocate for expanded access for teens.
-
Investigational Contraceptive Patch Clears FDA Panel Vote
Twirla, an investigational combined hormonal contraceptive patch, is under review by the FDA. In an October 2019 meeting, the patch received a 14 to 1 vote from the FDA’s Bone, Reproductive, and Urologic Drugs Advisory Committee.
-
FDA Approves Liletta IUD for Six Years of Effective Use
The FDA has approved the Liletta levonorgestrel intrauterine device (IUD) for six years of effective use. The 52 mg device, similar in size to the Mirena IUD, was approved for the U.S. in February 2015.